1 SUMMARY OF FINANCIAL STATEMENTS (Consolidated) First three quarters results for the fiscal year ending March 31, 2006 These financial statements have been prepared for reference only, in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited January 31, 2006 TSE Code: 4502 Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Inquiries: Toyoji Yoshida, Director General Manager President & COO: Yasuchika Hasegawa Corporate Communications Department Telephone: +81 6 6204-2060 / +81 3 3278-2039 1.Information relating to the preparation of quarterly financial statements 1) Adoption of simplified accounting treatments: Income tax expenses are calculated by multiplying quarterly income before income tax by the estimated tax rate for the fiscal year. 2) Differences in accounting treatments applied compared to previous consolidated fiscal year: Method of allocating operating expenses to business segments has been chang
Consolidated Financial Statements for the Interim Period of Fiscal 2005 November 4, 2005 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya (First Section of each), 1-1, Doshomachi 4-chome Fukuoka, Sapporo Chuo-ku, Osaka 540-8645, Japan Code number: 4502 URL: http://www.takeda.co.jp/ Board of Directors meeting: November 4, 2005 Representative: Yasuchika Hasegawa, President and COO Use of U.S. accounting standards: No Contact: Toyoji Yoshida, Director Telephone: +81-6-6204-2060, +81-3-3278-2039 1. Results for the Interim Period of Fiscal 2005 (April 1, 2005-September 30, 2005) (1) Sales and Income All amounts are rounded to the nearest million yen. Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Interim period of fiscal 2005 Interim